REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Peptide News

FDA updates, research breakthroughs, and industry developments

Peptide Contacts Disclaimer: The analyses and summaries on this page are generated using artificial intelligence and are provided for informational purposes only. AI-generated content may contain errors, omissions, or inaccuracies. Peptide Contacts does not independently verify the completeness or accuracy of AI-generated summaries. Readers should always consult the original source material for complete methodology, data, and findings. Nothing on this page constitutes medical, legal, or professional advice. Always consult a qualified healthcare provider before making any health-related decisions.

ClinicalTrials.gov: The U.S. government does not review or approve the safety and science of all studies listed on this website. ClinicalTrials.gov is maintained by the National Library of Medicine (NLM). Study sponsors and investigators submit their own information and are responsible for the safety, science, and accuracy of their listings. Before joining a study, talk to your health care professional about possible risks and benefits. Read the full ClinicalTrials.gov disclaimer.

Source Attribution: News items are sourced from FDA press releases, the Federal Register, STAT News, BioPharma Dive, ClinicalTrials.gov, and other public sources. Peptide Contacts curates and summarizes these items for informational purposes only. Always refer to the original source for complete details.

No news items yet

Check back soon for the latest in peptide research and regulation.